SUMMARY Serum amyloid A (SAA) was determined in 160 patients with cancer. Active disease was associated with high titre compared with the titre in non-active condition (31 8 v 5-8 mg/ml, respectively; p = 0 0002). SAA value showed a direct correlation with the stage of the disease: it was lowest at stages 1 and 2 and highest at the metastatic stage 4 (stage 1 v 4, p = 0.001; stage 2 v 3, p = 0'05). Cancers of the lung and unknown primary site were characterised by highly increased SAA concentration. Initial SAA value had prognostic significance: a value below 10 g/ml correlated with survival advantage, whereas a higher initial value indicated a greater likelihood of a poor outcome (actuarial survival analysis p < 0 001). When stage was accounted for, initial SAA value had significant prognostic bearing on survival of patients with advanced disease (stages 3 and 4) but not on that of patients with limited disease (stages 1 and 2). Serial testing showed good concordance between changes in SAA titre and clinical course. Fresh serum samples were deep frozen and thawed later for SAA assay. SAA concentrations were determined by radioimmunoassay using purified AA from human amyloidogenic spleen of a familial Mediterranean fever patient and rabbit antibody against human amyloid A. lodination of amyloid A was performed by the chloramine T method.9 The assay was carried out as previously described.'0 SAA titres were expressed in jg/ml amyloid A equivalent.
Data processing was aided by the SPSS programs. " Actuarial survival was computed by the Kaplan-Meier non-parametric method.'2 794 Serum amyloid A variations in patients with cancer Changes in SAA were in accordance with the clinical course in 38 of 47 (80 8%) cases.
Discussion
Several investigators collaborating with different laboratories studied SAA in malignancy and reported on its common increase in metastatic disease. Authors are not unanimous about the ability of SAA to distinguish between local and metastatic cancer, though reports favouring such an ability46 outnumber the discordant one.' Conceivably, this controversy stems from the study of patient populations that are heterogeneous with regard to specific malignancy, stage, and distribution of metastatic sites. Furthermore, nonuniform staging does not permit us to compare different studies with regard to either "local" or "metastatic" disease, unless clear definitions are given. The results of this study indicated that there is a concomitant rise in SAA value the more advanced the stage. Significant increase was found not only from stage I (early local disease) to stage 4 (metastatic disease) but also from stage 2 to stage 3, which is still non-metastatic, though usually incurable. Certain tumours-that is, cancers of the lung and of unknown primary site seem to produce a particularly high SAA titre that cannot be accounted for by advanced stage alone. The observation regarding lung cancer has been mentioned, though not emphasised, previously. For instance, Rosenthal found an appreciable increase in small cell bronchogenic cancer, even in limited disease.4
An important objective of the study was to explore the prognostic value of SAA assay. As actuarial survival shows, lower initial titre correlated with significant survival advantage, in contrast to higher titre, which had unfavourable prognostic bearing on patients. In addition, serial assessment disclosed good concordance of laboratory and clinical ranges. Remission after treatment was paralleled by a decrease in SAA, while progression was accompanied, in most cases, by an increase.
Although SAA is not a tumour specific marker and does not fulfil the criteria for an "ideal marker," 1 3 we feel that it has potential value in the initial assessment of patients with cancer who have active disease, as well as in the monitoring of therapeutic results. It could be helpful when other available markers such as CEA are negative; it may also be added to a panel of other markers to increase their diagnostic power.
The assay may be selectively applied in diseases such as lung cancer, in which high titres facilitate interpretation of results.
